Biobank for studying genetic factors in aortic stenosis and cardiovascular diseases
Translational-Omics in Aortic Stenosis (TOmAS) Biobank
This study is collecting samples and health information from people with aortic stenosis and other heart diseases to see if they can find new genetic clues that could improve diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10000 (estimated) |
| Ages | 19 Years and up |
| Sex | All |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre Academic / other |
| Locations | 2 sites (Montreal, Quebec and 1 other locations) |
| Trial ID | NCT05930899 on ClinicalTrials.gov |
What this trial studies
The TOmAS Biobank aims to collect and preserve biological materials, genetic material, and clinical data from patients with cardiovascular diseases, particularly aortic stenosis, as well as control participants. This observational study will facilitate future research into novel biomarkers using proteomic, transcriptomic, and epigenomic technologies. By analyzing these samples, researchers hope to uncover new insights into the genetic and physiological factors contributing to cardiovascular diseases, ultimately enhancing diagnosis and treatment options. The biobank will serve as a valuable resource for ongoing and future studies in this field.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with cardiovascular diseases who are undergoing cardiac surgery for non-aortic valve issues.
Not a fit: Patients with congenital heart disease will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this research could lead to the identification of new biomarkers that improve the prevention and treatment of cardiovascular diseases.
How similar studies have performed: Other studies utilizing biobanks and -omic technologies have shown promise in identifying biomarkers for cardiovascular diseases, suggesting a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * CVD diagnosis including, but not limited to: Aortic Stenosis, Coronary Heart Disease, Heart Failure, Atrial Fibrilation, Dilated Cardiomyopathy, Myocardial Infarction, and Spontaneous Coronary Artery Dissection. * Undergoing cardiac surgery for non-aortic valve pathology Exclusion Criteria: * Individuals with Congenital heart disease will be excluded
Where this trial is running
Montreal, Quebec and 1 other locations
- Montreal General Hospital — Montreal, Quebec, Canada (Recruiting)
- Royal Victoria Hospital — Montreal, Quebec, Canada (Recruiting)
Study contacts
- Study coordinator: George Thanassoulis, MD
- Email: george.thanassoulis@mcgill.ca
- Phone: 5149341934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.